Business Wire

MERCANS

Share
Mercans’ G2N Nova Solves Global Payroll Data Privacy Challenges

Mercans continues to disrupt the global payroll industry and solidify its leadership position by rolling out exciting new features to its flagship, G2N Nova payroll engine. The recently launched features include game-changing technology and address some of the biggest challenges of global payroll, including international data privacy compliance and processing latency limitations.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240123634878/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Mercans Unveils New Updates to Its Power-Packed Payroll Engine G2N Nova (Graphic: AETOSWire)

Mercans’ G2N Nova leverages groundbreaking stateless application architecture to enable completely anonymous payroll processing. This unprecedented technological approach enables processing gross-to-net payrolls without any sensitive Personal Identifiable Information (PII) ever being passed from clients to Mercans’ G2N Nova global payroll application.

The stateless application architecture has never before been successfully deployed in the global payroll industry, and G2N Nova, is the only payroll engine that is able to generate 100% accurate gross-to-net calculations for 100+ countries. And that’s not all, it does so through a single, native platform in real-time without accessing or storing any identifiable information related to employees. This evidently innovative, payroll technology solution completely overcomes the complex data privacy compliance requirements, as confidential employee data never leaves the clients’ systems and is not needed by G2N Nova for gross-to-net payroll calculations. Thus, proving its technological prowess and independence.

Additionally, this approach is a game-changer for the industry because data breaches and ransomware attacks have created concerns about data security and privacy in the payroll sector. These concerns have been significant hurdles for companies trusting external service or software providers for international payroll processing. G2N Nova’s stateless app architecture eliminates these concerns entirely. Clients’ PII never leaves their data centers and payroll-related information used by G2N Nova is completely anonymized.

G2N Nova upgrade also includes a ground-breaking Continuous Calc feature that fundamentally changes how payrolls are processed. Until now, all payrolls had to go through a multi-step payroll processing cycle. G2N Nova breaks this legacy paradigm and introduces real-time net pay. The Continuous Calc feature maintains full gross-to-net values for each employee in real-time and automatically updates the net pay amounts of employees whenever there is an update to an employee’s record. This feature, thus, eliminates the need to wait for a payroll processing cycle to be completed to determine an employee’s net pay for a period. The gross-to-net values for all employees will be always available in real-time.

In addition, the new version of G2N Nova lays a foundation for incorporating blockchain technology into payroll processes, allowing instantaneous and 100% tamper-proof verification of payroll calculations and payments using blockchain technology. Blockchain will create a permanent, unchangeable record of real-time record of all payroll transactions and amounts — so no one can alter or remove it. This revolutionary approach, thus, solidifies the foundation for third parties, including financial institutions, tax authorities, etc.

The new ground-breaking version of G2N Nova offers global, gross-to-net payroll processing capabilities across 100+ countries, making it the world’s most advanced and powerful native payroll engine. G2N Nova is available as a SaaS or service delivery platform that can be used as a stand-alone global payroll platform or deeply integrated with all major HCM or Workforce Management software solutions.

About Mercans

Mercans is a global leader in payroll technology. Mercans’ revolutionary global payroll engine G2N Nova enables Enterprise businesses & HCM providers to perform gross to-net calculations across 100+ legislation. To learn more about this innovative platform, visit www.mercans.com

LinkedIn

*Source: AETOSWire

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240123634878/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Alpega Group Completes Leadership Succession Plan Appointing Daniel Cohen New CEO8.1.2026 10:03:00 CET | Press release

Alpega Group, a leading pan-European provider of an end-to-end transportation and logistics platform, today announced a planned leadership transition. After a successful tenure as Chief Executive Officer, Todd DeLaughter will be retiring, stepping down from his role and transitioning to a Board Advisor role for the company. The Board of Directors has appointed Daniel Cohen as the incoming CEO, effective January 1st, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260108528648/en/ Daniel Cohen, CEO Alpega Daniel Cohen brings three decades of experience leading B2B SaaS businesses through periods of change, scale, and value realization. Most recently, as CEO of PayU, he led a full financial, operational, and cultural transformation returning the business to sustained profitable growth. He subsequently steered the company through a highly complex, multi-jurisdictional process that culminated in the successful sale to Rapyd

FPT Named Sitecore’s First Global Partner Under Global Elite Reseller Program8.1.2026 09:00:00 CET | Press release

Global IT Corporation FPT announced its appointment as the inaugural Global Elite Reseller under a new initiative from Sitecore that expands upon its successful Global Reseller Program. The Global Elite Reseller Program follows the launch of SitecoreAI, the next-generation digital experience platform that puts artificial intelligence at the center of marketing, unifying content, data, and personalization in one composable platform so organizations can reach, engage, and serve their audience across digital channels. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107425261/en/ Representatives from FPT and Sitecore at the Global Elite Reseller signing ceremony. Under the agreement, FPT will hold exclusive reseller rights in Vietnam and non-exclusive rights across select markets in Asia and the Middle East, taking SitecoreAI to market and showing how it helps teams plan, create, and optimize digital experiences using AI as cu

Natus Sensory Appoints Arne Boye Nielsen to Board of Directors8.1.2026 08:00:00 CET | Press release

Natus Sensory, a global leader in sensory and diagnostic solutions, today announced the appointment of Arne Boye Nielsen to its Board of Directors, effective January 1, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107392331/en/ Arne Boye Nielsen Arne brings more than 30 years of executive leadership experience in diagnostics and medical technology, most notably as President of Demant Diagnostics, where he built and scaled the business into a global leader over three decades. During his tenure, Arne played a central role in shaping Demant Diagnostics’ long-term strategy, portfolio expansion, and international growth, establishing it as a cornerstone of Demant’s global healthcare footprint. In addition to his executive leadership background, Arne brings extensive board experience. His deep expertise across diagnostics, governance, and value creation will further strengthen Natus Sensory’s Board as the company contin

4Moving Biotech Receives FDA IND Clearance for 4P004, Strengthening Its Position as a Leading Innovator in Disease-Modifying Osteoarthritis Therapeutics8.1.2026 07:30:00 CET | Press release

FDA IND clearance enabling the worldwide expansion of the INFLAM MOTION Phase 2a trial, involving major U.S. sites Advancing the first clinical proof of concept in OA with a first-in-class intra-articular GLP-1 agonist A holistic clinical strategy design establishing the foundation for a future accelerated approval pathway 4Moving Biotech (4MB), a clinical stage biotechnology company developing next-generation, disease-modifying therapies for osteoarthritis (OA), today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for 4P004, enabling the expansion of the Phase 2a INFLAM MOTION clinical trial into the United States (US). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107798042/en/ 4Moving Biotech (4MB), a clinical stage biotechnology company developing next-generation, disease-modifying therapies for osteoarthritis (OA), today announced that the U.S. F

Organon Enters into a Commercialization Agreement for Daiichi Sankyo’s Nilemdo®in France, Denmark, Iceland, Sweden, Finland and Norway8.1.2026 07:30:00 CET | Press release

The agreement builds on Organon’s cardiovascular disease portfolio, leveraging expertise to expand access to new treatments for patients with dyslipidemia, especially statin-intolerant patients.This collaboration addresses a critical gap in care that disproportionately affects women, who are at a 47% higher risk of developing statin intolerance compared to men.i Organon today announced that it has entered into an agreement with Daiichi Sankyo Europe to commercialize Nilemdo® (bempedoic acid) in France, Denmark, Iceland, Sweden, Finland and Norway. Nilemdo® is a new, first-in-class drug indicated for patients with high cholesterol and cardiovascular disease risk. It provides an alternative treatment for patients that cannot be treated effectively with statins.ii “This collaboration combines Organon’s commercial agility with Daiichi Sankyo’s expertise in cardiovascular innovation to bring Nilemdo® to patients in France, Denmark, Iceland, Sweden, Finland and Norway,” says Thibault Crosnie

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye